Jordan Ellis
Nusinersen, an antisense oligonucleotide, is the first drug approved to treat spinal muscular atrophy (SMA). SMA is a group of degenerative neuromuscular disorders with varying severities, ranging from neonatal onset with rapid progression to adolescent/adult onset with a slower clinical course. The drug was initially approved by the FDA in December 2016 and has since been approved in several countries, including Canada, Japan, Brazil, and China. The high cost of nusinersen, priced at US$125,000 per injection, has sparked debates among health authorities worldwide, with some deeming it unethically high. Despite the cost, nusinersen has demonstrated significant improvements in motor function and survival rates among infants with SMA Type 1, highlighting the importance of early intervention. As hospitals consider adding nusinersen to their formularies, they must weigh the benefits of this promising treatment against the financial challenges it poses.
| Characteristics | Values |
|---|---|
| Definition of Formulary | A continually updated list of medications and related information, representing the clinical judgment of pharmacists, physicians, and other experts in the diagnosis and treatment of disease and promotion of health. |
| Nusinersen | An antisense oligonucleotide administered directly into the cerebrospinal fluid to treat spinal muscular atrophy (SMA). |
| SMA | A group of autosomal recessively inherited degenerative neuromuscular disorders caused by loss-of-function mutations in the SMN1 gene, resulting in decreased levels of the SMN protein. |
| Mechanism of Action | Nusinersen modulates alternative splicing of the SMN2 gene, converting it into the SMN1 gene, and increasing the level of SMN protein in the central nervous system (CNS). |
| Distribution | Nusinersen distributes to the CNS and peripheral tissues. |
| Half-life | Estimated to be 135-177 days in cerebrospinal fluid and 63-87 days in blood plasma. |
| Elimination | The primary route of elimination is likely urinary excretion, with a half-life of 135-177 days in cerebrospinal fluid. |
| Metabolism | Metabolized via exonuclease-mediated hydrolysis and does not interact with CYP450 enzymes. |
| Cost | High cost of therapy, estimated at $750,000 for the first year and $375,000 annually thereafter, with a single dose costing $125,000. |
| Administration | Administration is complex and must be tailored to individual patients' needs, especially regarding pulmonary function and safety. |
| Safety | Hypersensitivity reactions, coagulation abnormalities, thrombocytopenia, and renal toxicity have been observed with nusinersen use. |
| Efficacy | Clinical trials have demonstrated significant improvements in motor function and survival rates, especially with early intervention. |
| Regulatory Approval | Approved by the FDA and EMA for the treatment of SMA, with ongoing applications for a higher-dose regimen. |
Explore related products
What You'll Learn
Nusinersen's high cost of therapy
Nusinersen is a drug used to treat spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease. SMA patients have mutations in the survival motor neuron (SMN) gene, which codes for the SMN protein. The drug increases the level of SMN protein in the central nervous system (CNS) by modulating alternative splicing of the SMN2 gene, functionally converting it into the SMN1 gene.
The high cost of nusinersen therapy is a significant concern for healthcare systems and patients alike. In the United States, the list price of nusinersen is US$125,000 per injection, resulting in a treatment cost of US$750,000 in the first year and US$375,000 annually thereafter. These figures do not include the substantial medical costs associated with the administration of the medication, which can be complex and must be tailored to individual patients' needs. The New York Times has reported that nusinersen is among the most expensive drugs in the world.
The high price of nusinersen has led to debates about its cost-effectiveness and ethical implications. Several countries and organizations have weighed in on the matter. For example, in October 2017, Danish authorities recommended nusinersen only for a small subset of people with SMA Type 1 (young babies) due to its high price, and the National Institute for Health and Care Excellence (NICE) in the UK initially recommended against offering nusinersen to SMA patients in 2018. Similarly, the Irish Health Service Executive decided in February 2019 that nusinersen was too expensive, estimating a cost of €600,000 per patient in the first year and €380,000 annually thereafter, with a significant budget impact.
On the other hand, proponents of nusinersen argue that its high cost is justified by its effectiveness in treating SMA. Clinical trials have shown significant improvements in motor function and survival rates, especially with early intervention. In some cases, nusinersen has been found to halt disease progression and improve motor-milestone responses in treated patients. Additionally, nusinersen is the first drug to treat SMA, and its "orphan drug" designation in the United States and the European Union may have influenced pricing decisions.
The cost-effectiveness of nusinersen is a complex issue that requires careful consideration of various factors, including survival rates, quality-adjusted life years (QALYs), and healthcare costs. While nusinersen has shown promising results in treating SMA, the availability and accessibility of the drug continue to be influenced by its high cost and the ongoing debates surrounding its cost-effectiveness.
Capital Regional Hospital: Tallahassee's Healthcare Hub
You may want to see also
Explore related products
The drug's efficacy in treating SMA
Spinal muscular atrophy (SMA) is a group of inherited neurological disorders that begin in infancy or childhood and lead to the degeneration of spinal motor neurons, resulting in weakness, muscle wasting, and, in severe cases, paralysis and death before the age of two. SMA affects approximately 1 in 10,000 newborns and is a leading genetic cause of death in infants and toddlers.
Nusinersen, marketed as Spinraza® in the U.S., is the first therapy approved for the treatment of SMA. It was approved by the FDA in December 2016 and by the EMA in May 2017, becoming the first drug to treat SMA. The drug is administered directly into the cerebrospinal fluid and modulates the alternative splicing of the SMN2 gene, converting it into the SMN1 gene, and increasing the level of SMN protein in the CNS. This is important because SMA is caused by loss-of-function mutations in the SMN1 gene, which can be partially compensated for by the SMN2 gene.
The efficacy of nusinersen in treating SMA has been demonstrated in multiple clinical trials. In a Phase 3 trial in infants with SMA Type 1, treated infants showed significant improvement in motor function within six months, compared to no improvement in infants receiving a placebo. A second Phase 3 trial in children with SMA Type 2 also met its primary endpoint early, with some children achieving milestones. These trials demonstrated that nusinersen can lead to meaningful improvements in overall motor functions, with a majority of infants being motor milestone responders at 13 months.
The benefits of nusinersen are further emphasized by its ability to improve survival rates. Event-free survival, defined as not requiring invasive ventilation or death, was found to be higher in the treated group, especially when treatment was initiated early. This underscores the importance of prompt treatment with nusinersen to achieve optimal clinical outcomes.
However, it is important to note that the logistics of administering nusinersen to patients with SMA can be complex. The fragile nature of their pulmonary status requires optimization before beginning treatment. Additionally, some SMA patients may not be able to receive nusinersen through a routine lumbar puncture due to scoliosis or other positioning difficulties. The high cost of the medication, estimated at $750,000 for the first year and $375,000 annually thereafter, is also a significant consideration when deciding whether to include nusinersen in a hospital formulary.
County Hospitals: Government-Run or Private?
You may want to see also
Explore related products
Potential side effects and safety concerns
While nusinersen has been approved by the FDA and EMA to treat SMA, a degenerative neuromuscular disorder, it is associated with several potential side effects and safety concerns. The most common adverse reactions observed in clinical studies include lower respiratory infection, fever (pyrexia), constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. It is worth noting that side effects may vary among individuals, and some may be more prone to experiencing these effects than others.
One notable safety concern is the risk of bleeding problems, which can manifest as bleeding gums, pinpoint red spots on the skin, or unexpected bruising or weakness. Severe kidney problems may also occur, requiring immediate medical attention. Additionally, in 2018, several cases of communicating hydrocephalus in children and adults treated with nusinersen were reported, although it remains unclear if this was directly drug-related.
The cost of nusinersen therapy is another significant consideration, with a single dose priced at US$125,000, amounting to a treatment cost of US$750,000 in the first year and US$375,000 annually thereafter. This high cost has led to debates about funding and cost-effectiveness, with some authorities refusing to fund the medication due to its expensive nature.
Furthermore, the logistics of administering nusinersen can be complex, particularly for patients with SMA who may have positioning difficulties due to scoliosis. It is crucial to optimise pulmonary function before initiating treatment, and strategies are needed to ensure patient safety during administration. While nusinersen has demonstrated benefits in clinical trials, particularly with early intervention, it is essential to carefully weigh the potential side effects and safety concerns against the expected benefits for each patient.
Understanding Hospital Discharge: Paperwork Simplified
You may want to see also
Explore related products
Administration considerations and complexities
The first and foremost challenge when considering the addition of nusinersen to a hospital formulary is the cost of therapy. Nusinersen is among the most expensive drugs in the world, with a list price of US$125,000 per injection, resulting in a treatment cost of US$750,000 in the first year and US$375,000 annually thereafter. This high cost has led to funding rejections in several countries, including Norway and Ireland, and limited recommendations for use in Denmark.
The administration of nusinersen is complex and requires careful consideration of the overall medical system and resources available. The fragile pulmonary status of patients with spinal muscular atrophy (SMA) necessitates optimisation of pulmonary function before initiating treatment. Furthermore, some SMA patients may have scoliosis or other positioning difficulties, requiring support from Interventional Radiology for drug administration. The development and implementation of a comprehensive clinical practice guideline for nusinersen administration can take several months and require input from various medical specialists.
The drug is administered directly into the cerebrospinal fluid, and the protocol may need to be adjusted for individual patients based on their specific care needs. The medication is typically given as four loading doses over approximately 60 days, followed by maintenance dosing every four months. Each dose consists of 12 mg (5 mL) withdrawn from a single-dose vial into a syringe, with the vial's contents inspected for any discoloration or particulate matter before administration.
Additionally, there are potential adverse effects associated with nusinersen. Cases of communicating hydrocephalus in children and adults treated with nusinersen have been reported, although it is unclear if this is drug-related. Renal toxicity, including potentially fatal glomerulonephritis, has been observed with similar drugs. Coagulation abnormalities and thrombocytopenia have also been observed, increasing the risk of bleeding complications. As such, quantitative spot urine protein testing is recommended before initiating treatment and prior to each dose to monitor for any abnormalities.
Nursing and Drug Testing: How Often?
You may want to see also
Explore related products
The impact on hospital stay duration and cost-effectiveness
Nusinersen, marketed as Spinraza, is a medication used to treat spinal muscular atrophy (SMA), a rare neuromuscular disorder. The drug is administered directly to the central nervous system (CNS) using intrathecal injection. In clinical trials, the drug was found to halt the progression of the disease and improve motor function in around 60% of infants affected by type 1 SMA.
The impact of nusinersen on hospital stay duration is variable. If the procedure is straightforward and has been performed multiple times, a short hospital stay may be adequate. However, for first-time treatments or more complicated cases, a longer hospital stay may be necessary. Additionally, if sedation is required, an extended hospital stay may be warranted.
Regarding cost-effectiveness, nusinersen has been deemed expensive by several authorities. The list price in the USA is US$125,000 per injection, resulting in a treatment cost of US$750,000 in the first year and US$375,000 annually thereafter. This pricing has led to debates about the drug's cost-effectiveness and affordability for healthcare systems. For instance, in 2017, Danish and Norwegian authorities recommended against offering nusinersen as a standard treatment for SMA due to its high price relative to the benefits. Similarly, in 2019, the Irish Health Service Executive concluded that nusinersen was too expensive, estimating a budget impact of over €20 million over five years for the 25 children with SMA in Ireland.
On the other hand, nusinersen's cost-effectiveness should also consider the potential reduction in hospital stays and the value of improved motor function and survival rates. A study by ICER compared the cost-effectiveness of nusinersen to best supportive care (BSC) in patients with infantile-onset SMA in the US. The base-case analysis showed that nusinersen achieved greater quality-adjusted life years (QALYs) and life years (LYs) compared to BSC, resulting in a higher incremental cost per QALY and LY gained. However, the cost-effectiveness ratios remained high even in sensitivity analyses, exceeding traditional cost-effectiveness thresholds.
In conclusion, while nusinersen has demonstrated effectiveness in treating SMA, its impact on hospital stay duration is variable, depending on the specifics of each case. The drug's cost-effectiveness is a subject of debate due to its high price, with some authorities deeming it unaffordable or recommending its use only in specific subsets of patients. However, the potential long-term benefits of nusinersen, such as improved motor function and survival rates, should also be considered when evaluating its overall cost-effectiveness.
Who's in Charge: Doctors' Authority in Hospitals?
You may want to see also
Frequently asked questions
Nusinersen is a drug used to treat spinal muscular atrophy (SMA). It is administered directly into the cerebrospinal fluid and alters SMN2 pre-RNA splicing to increase the expression of functional SMN protein.
Nusinersen has been shown to be effective in treating SMA, with significant improvements in motor function and survival rates, particularly in infants with SMA Type 1. It is also the first drug to be approved by the FDA and EMA for the treatment of SMA.
The high cost of therapy is a significant challenge, with the medication costing up to USD 750,000 in the first year and 375,000 annually thereafter. Additionally, the complex logistics of administering nusinersen to patients with SMA and ensuring their safety should be carefully considered.
Nusinersen has been approved for the treatment of SMA in several countries, including the United States, Canada, Japan, Brazil, Switzerland, China, and others. However, some countries, such as Denmark and Norway, have initially rejected funding due to the high price of the medication.
